HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 50.4%

Neg 50.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.